Etomidate anesthesia linked to higher short-term death risk after hip surgery

Etomidate, one of the most widely used induction agents in modern anesthesia, has long been prized for a seemingly simple reason: it leaves the cardiovascular system almost untouched. For elderly patients with a broken hip, many of whom arrive in the operating room fragile, dehydrated, and teetering on the edge of hemodynamic collapse, that stability can look like a lifesaver. But a new large-scale cohort study suggests the drug may carry a hidden cost, one written in the language of hormones rather than blood pressure. The research, published in Scientific Reports, links perioperative etomidate exposure to a significantly higher risk of death within 30 days of hip fracture surgery, reigniting a decades-old debate about whether a single bolus of anesthetic can shape surgical survival.

The study, led by anesthesiologists Kuo-Chuan Hung, Li-Chen Chang, and I-Wen Chen at Chi Mei Medical Center in Taiwan, mined the TriNetX Research Network, a global database aggregating electronic health records from millions of patients across multiple healthcare systems. The team identified adults undergoing hip fracture surgery and compared those who received etomidate during the perioperative period with those who did not. Because patients given etomidate are often sicker to begin with, the researchers used 1:1 propensity score matching, a statistical technique that pairs each etomidate patient with a control patient of nearly identical baseline characteristics, including age, comorbidities, and medication history. After matching, 6,246 patients populated each group, with balanced covariates that allowed the comparison to approximate a randomized trial.

The primary outcome was stark: 30-day mortality. Patients exposed to etomidate had a 35 percent higher odds of dying within a month of surgery compared with matched controls, with an odds ratio of 1.35 and a 95 percent confidence interval of 1.15 to 1.60, a result the authors describe as statistically robust. Secondary outcomes told a more nuanced story. Etomidate exposure was associated with increased odds of postoperative pneumonia, at an odds ratio of 1.23, and major adverse cardiovascular events, or MACEs, at an odds ratio of 1.20. Curiously, the drug appeared protective for acute kidney injury, with an odds ratio of 0.83, while no significant association emerged for sepsis or venous thromboembolism.

What makes these findings biologically plausible is etomidate’s well-documented effect on the adrenal cortex. Even a single induction dose can suppress the enzymatic machinery, specifically 11-beta-hydroxylase, responsible for cortisol and aldosterone synthesis. This adrenal suppression is usually transient, lasting between 12 and 24 hours, but in elderly patients with limited physiological reserve, even a brief hormonal blackout may impair the body’s ability to mount a stress response to surgical trauma. The result, researchers hypothesize, could be a cascade of immune dysfunction, impaired wound healing, heightened susceptibility to infection, and cardiovascular instability, all of which align with the observed increases in mortality, pneumonia, and cardiac events.

The kidney finding, however, complicates the narrative. Why would a drug associated with worse outcomes simultaneously reduce the risk of acute kidney injury? The authors suggest several possibilities. Etomidate’s hemodynamic stability may preserve renal perfusion during the critical induction window, when other agents like propofol can precipitate hypotension and subsequent renal hypoperfusion. Alternatively, the adrenal suppression itself might alter fluid balance or inflammatory pathways in ways that protect the kidneys. The paradox underscores how a single drug can exert divergent effects across organ systems, and it cautions against interpreting any single outcome in isolation.

Perhaps the most reassuring aspect of the study is what happened when the researchers extended the follow-up window. Between 30 and 180 days after surgery, all associations between etomidate and adverse outcomes attenuated and lost statistical significance. This temporal pattern suggests the drug’s harms, if real, are concentrated in the immediate postoperative period, when adrenal suppression is most pronounced. It also implies that etomidate does not leave a lasting biological scar, but rather a transient vulnerability that the body either overcomes or succumbs to within the first few weeks of recovery.

The study is not without limitations. As a retrospective cohort analysis, it cannot establish causation, only association. Although propensity matching balanced measured confounders, unmeasured variables, such as the specific reason an anesthesiologist chose etomidate over an alternative agent, may still influence results. Patients selected for etomidate might have had subtle hemodynamic instability not captured in the database, a phenomenon known as confounding by indication. Additionally, the TriNetX database, while vast, reflects the coding practices and patient populations of participating institutions, which may limit generalizability to other healthcare settings.

Despite these caveats, the findings carry significant clinical weight. Hip fracture surgery is performed on hundreds of thousands of elderly patients worldwide each year, and 30-day mortality rates hover around 10 percent in many populations, making even modest increases in risk clinically meaningful. An odds ratio of 1.35, applied across a global surgical population, could translate into thousands of excess deaths if the association is causal. The authors explicitly call for prospective confirmation, ideally through a randomized controlled trial comparing etomidate with alternative induction agents in this vulnerable population.

The debate over etomidate is not new. Anesthesiologists have argued for decades about whether its adrenal suppression is clinically consequential or merely a biochemical curiosity. Previous studies have yielded conflicting results, with some finding increased mortality and others detecting no signal. This new analysis, with its large sample size and rigorous matching, adds considerable heft to the side of concern, while the kidney finding adds a layer of complexity that resists simple narratives. The drug’s future in hip fracture anesthesia may now hinge on whether the anesthesia community views transient hormonal suppression as an acceptable trade-off for cardiovascular stability, or as a preventable harm.

For now, the study serves as a reminder that in the fragile physiology of the elderly surgical patient, even brief pharmacological perturbations can ripple outward in unexpected ways. As the authors conclude, perioperative etomidate exposure was associated with worse short-term postoperative outcomes, with the notable exception of reduced acute kidney injury risk. Whether this signal survives the scrutiny of prospective trials remains to be seen, but for clinicians choosing an induction agent at 3 a.m. for an 85-year-old with a fractured femur, the calculus just became considerably more complicated.

Subject of Research: Association of perioperative etomidate exposure and mortality after hip fracture surgery: a matched cohort study

Article Title: Association of perioperative etomidate exposure and mortality after hip fracture surgery: a matched cohort study

Article References: Hung, K.-C., Chang, L.-C., & Chen, I.-W. (2026). Association of perioperative etomidate exposure and mortality after hip fracture surgery: a matched cohort study. Scientific Reports. https://doi.org/10.1038/s41598-026-76442-8

Image Credits: AI Generated

DOI: 10.1038/s41598-026-76442-8

Keywords: Association, perioperative, etomidate, exposure, mortality, fracture, surgery, matched, cohort, scientific research